Chinese Innovative Drug and CRO Stocks Surge; Multiple Names Up Over 10%

The breadth of the move — beyond a single catalyst name to CRO and biologics platforms alike — suggests investors are repricing the sector as a group rather than trading one headline. That matters because CRO names are levered to global pharma R&D budgets, while innovative drug names track domestic approval and reimbursement cycles, so a synchronized rally implies either a policy signal or a liquidity shift is doing the work. Whether the gains hold once the initial flow fades, and whether the CRO side decouples from the drug side, is the open question.